LAMP2 and myeloid sarcoma: In this study, we firstly analyzed CSF from individuals with MS and NMOSD using proteomics, and identified two novel possible biomarkers (IGFBP7 and LAMP2) that might be utilized to diagnose NMOSD and MS and to differentiate NMOSD from MS.